Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
The replication-competent recombinant vesicular stomatitis virus (rVSV)–based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and immunogenicity testing before its use in West Africa.
We performed three open-label, dose-escalation phase 1 trials and one randomized, double-blind, controlled phase 1 trial to assess the safety, side-effect profile, and immunogenicity of rVSV-ZEBOV at various doses in 158 healthy adul...
- Publication status:
- Peer review status:
- Peer reviewed
(Version of record, pdf, 823.5KB)
- Publisher copy:
- Pubs id:
- Local pid:
- Deposit date:
- Copyright holder:
- Massachusetts Medical Society
- Copyright date:
- Copyright © 2016 Massachusetts Medical Society. All rights reserved. A full list of authors is available from the MMS.
If you are the owner of this record, you can report an update to it here: Report update to this record